National Center for Injury Prevention and Control,
WISQARS Leading Causes of Death Reports 2007.
H.C.; Marfan's syndrome.
E.R.; A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2.
O.M.; Ascending aortic dilatation associated with bicuspid aortic valve: pathophysiology, molecular biology, and clinical implications.
van de Laar
G.; Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis.
C.; Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms.
Van der Linde
M., van de Laar
J.; Saccular aneurysm within a persistent ductus arteriosus.
Reference Values for Arterial Stiffness' Collaboration,
Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values.'.
Van de Laar
I.M., Van der Linde
E.H.; Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome.
T.; Aneurysm syndromes caused by mutations in the TGF-beta receptor.
D.M.; Neuroradiologic manifestations of Loeys-Dietz syndrome type 1.
A.; Evidence for Marfan cardiomyopathy.
S.; TGF-beta1 and angiotensin networking in cardiac remodeling.
O.; Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF-β.
R.; Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia.
T.; Atrial fibrosis and atrial fibrillation: the role of the TGF-β1 signaling pathway.
S.D.; TGFβ signaling and congenital heart disease: insights from mouse studies.
J.; Heart valve development: endothelial cell signaling and differentiation.
B.L.; B-type natriuretic peptide attenuates cardiac hypertrophy via the transforming growth factor-β1/smad7 pathway in vivo and in vitro.
L.F.; Natriuretic peptide levels predict recurrence of atrial fibrillation after radiofrequency catheter ablation.
D., van Kuijk
W.J.; Usefulness of repeated N-terminal pro-B-type natriuretic peptide measurements as incremental predictor for long-term cardiovascular outcome after vascular surgery.
S.K.; Assessment of aortic stiffness in Marfan syndrome using two-dimensional and Doppler echocardiography.
C.; Endothelial function, carotid-femoral stiffness, and plasma matrix metalloproteinase-2 in men with bicuspid aortic valve and dilated aorta.
M.; Augmentation index and the evolution of aortic disease in Marfan-like syndromes.
C.; ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).
H.C.; Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.
J.A.; 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine.
M.; Long-term results of aortic valve-sparing operations for aortic root aneurysm.